Article thumbnail

Are Antiplatelet Effects of Clopidogrel Inhibited by Atorvastatin? A Research Question Formulated but Not Yet Adequately Tested

By Victor L. Serebruany, Phd Steven, R. Steinhubl, Md Charles and H. Hennekens

Abstract

With respect to antiplatelet therapy, randomizedtrials and their meta-analyses1 indicate benefits ofclopidogrel either as an alternative2 or an adjunct3 to aspirin in some high-risk patients. Regarding the metabolic pathways of clopidogrel, the active thiol metabolite binds rapidly and irreversibly to platelet adenosine diphosphate (ADP) receptors, thus inhibiting platelet aggregation.4 Clopi-dogrel, a thienopyridine, is a platelet ADP-receptor blocker that is known to be beneficial during and after coronary stenting.2–5 Clopidogrel is extensively metabolized by the liver. The main circulating metabolite is the carboxylic acid derivative, which has no effect on platelet aggregation. The active metabolite, a thiol derivative, is formed by oxidation of clopidogrel to 2-oxo-clopidogrel and subsequent hydrolysis. Results of in vitro studies in human liver microsomes and recombinant cytochromes P450 have shown that several cytochromes are involved in the oxidative metabolism o

Year: 2016
OAI identifier: oai:CiteSeerX.psu:10.1.1.1015.5571
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://circ.ahajournals.org/co... (external link)
  • http://circ.ahajournals.org/co... (external link)
  • http://citeseerx.ist.psu.edu/v... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.